Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis

被引:5
|
作者
Yang, Huili [1 ,2 ]
Feng, Lian [1 ,2 ]
Xu, Linyi [1 ,2 ]
Jiang, Dansheng [1 ,2 ]
Zhai, Fenfen [3 ]
Tong, Guangdong [1 ]
Xing, Yufeng [1 ]
机构
[1] Shenzhen Tradit Chinese Med Hosp, Hepatol Dept, Shenzhen 518033, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen 518033, Guangdong, Peoples R China
[3] Shenzhen Futian Ctr Chron Dis Control, Shenzhen 518048, Guangdong, Peoples R China
关键词
APOLIPOPROTEIN-B; PPAR-ALPHA; MICROBIOTA; METABOLISM; PROGRESSION; DEFICIENCY; DISORDERS; BACTERIA; RECEPTOR; OBESITY;
D O I
10.1155/2022/4801695
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing incidence rate but few therapies. Shugan Xiaozhi decoction (SX) has demonstrated beneficial effects in treating NAFLD with an unclear mechanism. This study was aimed at investigating the therapeutic mechanism of SX on high-fat diet-induced NAFLD rats via the gut-liver axis. Hepatic steatosis and integrity of intestinal mucosa in NAFLD rats were assessed by histopathological staining. The level of lipid and inflammation were estimated by enzyme-linked immunosorbent assay. Western Blotting was used to detect apolipoprotein (apo) B48 expression. 16S rRNA analysis was used to measure the changes of gut microbial composition after SX treatment. The expressions of zona occludens 1 protein (ZO-1), occludin, and secretory immunoglobulin A (sIgA) in the colon were detected by immunostaining to investigate the intestinal barrier function. Our study found that SX reduced hepatic steatosis, the levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, and triglyceride and apoB48 expression but increased peroxisome proliferator activated receptor alpha (PPAR alpha) level. Moreover, SX altered the diversity of gut microbiota, upregulating the relative abundance of f_Prevotellaceae, while downregulating f_Bacteroidales_ S24-7, f_Lachnospiraceae, f_Ruminococcaceae, f_Erysipelotrichaceae, and f_Desulfovibrionaceae. By increasing the expression of ZO-1 and occludin and decreasing the level of proinflammatory factors, including sIgA, lipopolysaccharide, tumor necrosis factor-alpha, interleukin-1 beta, monocyte chemotactic protein-1, and transforming growth factor-beta 1, SX improved intestinal mucosal integrity and barrier function. Our study illustrated that the gut-liver axis was a potential way for SX to ameliorate NAFLD, that is, by regulating the expression of PPAR alpha, apoB48, and modulating gut microbiota to protect the intestinal barrier function, and thus alleviate lipid deposition and inflammatory response in the liver.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?
    Dong, Tien S.
    Jacobs, Jonathan P.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2019, 244 (06) : 408 - 418
  • [32] Gut-liver axis in inflammatory bowel disease
    Egresi Anna
    Kovacs Agota
    Szilvas Agnes
    Blazovics Anna
    ORVOSI HETILAP, 2017, 158 (26) : 1014 - 1021
  • [33] New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease
    Bertran, Laia
    Jorba-Martin, Rosa
    Barrientos-Riosalido, Andrea
    Portillo-Carrasquer, Marta
    Aguilar, Carmen
    Riesco, David
    Martinez, Salome
    Vives, Margarita
    Sabench, Fatima
    Del Castillo, Daniel
    Richart, Cristobal
    Auguet, Teresa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [34] Original Research A rise in Proteobacteria is an indicator of gut-liver axis-mediated nonalcoholic fatty liver disease in high-fructose-fed adult mice
    Vasques-Monteiro, Isabela Macedo Lopes
    Silva-Veiga, Flavia Maria
    Miranda, Carolline Santos
    Goncalves, Edira Castello Branco de Andr ade
    Daleprane, Julio Beltrame
    Souza-Mello, Vanessa
    NUTRITION RESEARCH, 2021, 91 : 26 - 35
  • [35] Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
    Nair, Bhagyalakshmi
    Kamath, Adithya Jayaprakash
    Tergaonkar, Vinay
    Sethi, Gautam
    Nath, Lekshmi R.
    LIFE SCIENCES, 2024, 351
  • [36] MDG-1, an Ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis
    Wang, Xu
    Shi, Linlin
    Wang, Xinping
    Feng, Yi
    Wang, Yuan
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2019, 141 : 1013 - 1021
  • [37] Deciphering the Gut-Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease
    Singh, Samradhi
    Kriti, Mona
    Catanzaro, Roberto
    Marotta, Francesco
    Malvi, Mustafa
    Jain, Ajay
    Verma, Vinod
    Nagpal, Ravinder
    Tiwari, Rajnarayan
    Kumar, Manoj
    LIVERS, 2024, 4 (03): : 435 - 454
  • [38] Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis
    Jiang, Jian-Wen
    Chen, Xin-Hua
    Ren, Zhigang
    Zheng, Shu-Sen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (01) : 19 - 27
  • [39] Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
    Pezzino, Salvatore
    Sofia, Maria
    Faletra, Gloria
    Mazzone, Chiara
    Litrico, Giorgia
    La Greca, Gaetano
    Latteri, Saverio
    BIOLOGY-BASEL, 2022, 11 (11):
  • [40] Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease
    Aqel, Bashar
    DiBaise, John K.
    NUTRITION IN CLINICAL PRACTICE, 2015, 30 (06) : 780 - 786